BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28428725)

  • 1. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
    Rimassa L; Reig M; Abbadessa G; Peck-Radosavljevic M; Harris W; Zagonel V; Pastorelli D; Rota Caremoli E; Porta C; Damjanov N; Patel H; Daniele B; Lamar M; Schwartz B; Goldberg T; Santoro A; Bruix J
    World J Gastroenterol; 2017 Apr; 23(13):2448-2452. PubMed ID: 28428725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges of advanced hepatocellular carcinoma.
    Colagrande S; Inghilesi AL; Aburas S; Taliani GG; Nardi C; Marra F
    World J Gastroenterol; 2016 Sep; 22(34):7645-59. PubMed ID: 27678348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
    Rastogi A
    World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
    Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma.
    Liu TH; Shao YY; Lu LC; Shen YC; Hsu C; Lin ZZ; Hsu CH; Cheng AL
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):615-621. PubMed ID: 31132887
    [No Abstract]   [Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in predictive biomarkers for hepatocellular carcinoma therapy.
    Casadei-Gardini A; Orsi G; Caputo F; Ercolani G
    Expert Rev Anticancer Ther; 2020 Jan; 20(1):63-74. PubMed ID: 31910040
    [No Abstract]   [Full Text] [Related]  

  • 9. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Kis B; El-Haddad G; Sheth RA; Parikh NS; Ganguli S; Shyn PB; Choi J; Brown KT
    Cancer Control; 2017; 24(3):1073274817729244. PubMed ID: 28975829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
    Colombo M; Raoul JL; Lencioni R; Galle PR; Zucman-Rossi J; Bañares R; Seehofer D; Neuhaus P; Johnson P
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):639-51. PubMed ID: 23628963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multidisciplinary approach: group dynamics.
    Taddei TH
    J Clin Gastroenterol; 2013 Jul; 47 Suppl():S27-9. PubMed ID: 23632364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated treatment approach to hepatocellular carcinoma.
    Llovet JM
    J Gastroenterol; 2005 Mar; 40(3):225-35. PubMed ID: 15830281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
    Lehrich BM; Zhang J; Monga SP; Dhanasekaran R
    J Hepatol; 2024 Mar; 80(3):515-530. PubMed ID: 38104635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma.
    Venook AP
    Curr Treat Options Oncol; 2000 Dec; 1(5):407-15. PubMed ID: 12057148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
    Eggert T; Greten TF
    Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes.
    Iñarrairaegui M; Melero I; Sangro B
    Clin Cancer Res; 2018 Apr; 24(7):1518-1524. PubMed ID: 29138342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Management of Hepatocellular Carcinoma.
    Rich NE; Yopp AC; Singal AG
    J Oncol Pract; 2017 Jun; 13(6):356-364. PubMed ID: 28605614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
    Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
    World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.